Sex differences in lipid profiles in relation to the progression of glucose abnormalities

Journal of Diabetes

Volumn 4, Issue 1, 2012, Pages 95-101

  Carnevale Schianca, Gian P ^a   Fra, Gian P ^a   Colli, Elena ^a   Bigliocca, Marcello ^a   Mella, Roberto ^a   Scaglia, Elena ^a   Bartoli, Ettore ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

Dyslipidemia; Gender; Prediabetes; Type 2 diabetes mellitus

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RISK ASSESSMENT; SEX DIFFERENCE; SMOKING; WAIST CIRCUMFERENCE;

ADULT; AGED; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; FEMALE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; LIPIDS; MALE; MIDDLE AGED; SEX CHARACTERISTICS;

EID: 84857393403     PISSN: 17530393     EISSN: 17530407     Source Type: Journal    
DOI: 10.1111/j.1753-0407.2011.00160.x     Document Type: Article

References (33)

1. Kannel WB, McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease: The Framingham study. Diabetes Care. 1979; 2: 120-6.
2. Wenger NK. Hypertension and other cardiovascular risk factors in women. Am J Hypertens. 1995; 8 (Suppl. 1): S94-9.
3. Huxley R, Barzi F, Woodfard M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: Meta-analysis of 37 prospective cohort studies. BMJ. 2006; 332: 73-8.
4. Yusuf S, Hawken S, Öunpuu S et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet. 2004; 364: 937-52.
5. Kanaya AM, Grady D, Barret-Connor E. Explaining the sex difference in coronary heart disease mortality among patients with type 2 diabetes mellitus: A meta-analysis. Arch Intern Med. 2002; 162: 1737-45.
6. Resnick HE, Howard BV. Diabetes and cardiovascular disease. Annu Rev Med. 2002; 53: 245-67.
7. Ferrara A, Williamson DF, Karter AJ, Thompson TJ, Kim C, for the TRIAD Study Group. Sex differences in quality of health care related to ischemic heart disease prevention in patients with diabetes. The translating research into action for diabetes (TRIAD) study, 2000-2001. Diabetes Care. 2004; 27: 2974-2976.
8. Siegel RD, Cupples A, Schaefer EJ, Wilson PW. Lipoproteins, apolipoproteins, and low-density lipoprotein size among diabetics in the Framingham offspring study. Metabolism. 1996; 45: 1267-72.
9. Howard BV, Cowan LD, Go O, Welty TK, Robbins DC, Lee ET. Adverse effects of diabetes on multiple cardiovascular disease risk factors in women: The Strong Heart Study. Diabetes Care. 1998; 21: 1258-65.
10. Grundy SM, Hansen B, Smith SC Jr, Cleeman JI, Khan RA, for Conference Participants. Clinical management of metabolic syndrome: Report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association on scientific issues related to management. Circulation. 2004; 4: 551-6.
11. The Expert Committee on the Diagnosis Classification of Diabetes Mellitus. Follow-up report on the diagnosis and classification of diabetes mellitus. Diabetes Care. 2003; 26: 3160-7.
12. Carnevale Schianca GP, Rossi A, Sainaghi PP, Maduli E, Bartoli E. The significance of impaired fasting glucose versus impaired glucose tolerance. Importance of insulin secretion and resistance. Diabetes Care. 2003; 26: 1333-7.
13. Festa A, D'Agostino R Jr, Hanley AJ, Karter AJ, Saad MF, Haffner SM. Differences in insulin resistance in nondiabetic subjects with isolated impaired glucose tolerance or isolated impaired fasting glucose. Diabetes. 2004; 53: 1549-55.
14. Nóvoa FJ, Boronat M, Saavedra P et al. Differences in cardiovascular risk factors, insulin resistance, and insulin secretion in individuals with normal glucose tolerance and in subjects with impaired glucose regulation. The Telde Study. Diabetes Care. 2005; 28: 2388-93.
15. Unwin N, Shaw J, Zimmet P, Alberti KG. Impaired glucose tolerance and impaired fasting glycaemia: The current status on definition and intervention. Diabet Med. 2002; 19: 708-23.
16. Walldius G, Jungner I. The apoB/apoA-I ratio: A strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy. A review of the evidence. J Intern Med. 2006; 259: 493-519.
17. Stumvoll M, Van Haeften T, Fritsche A, Gerich J. Oral glucose tolerance test indexes for insulin sensitivity and secretion based on various availabilities of sampling times. Diabetes Care. 2001; 24: 796-7.
18. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28: 412-9.
19. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modelling. Diabetes Care. 2004; 27: 1487-95.
20. Haffner SM, Kennedy E, Gonzalez C, Stern MP, Miettinen H. A prospective analysis of the HOMA model. The Mexico City Diabetes Study. Diabetes Care. 1996; 19: 1138-41.
21. Gutt M, Davis CL, Spitzer SB et al. Validation of the insulin sensitivity index [ISI (0, 120)]: Comparison with other measures. Diabetes Res Clin Pract. 2000; 47: 177-84.
22. Carnevale Schianca GP, Sainaghi PP, Castello L, Rapetti R, Limoncini AM, Bartoli E. Comparison between HOMA-IR and ISI-gly in detecting subjects with the metabolic syndrome. Diabetes Metab Res Rev. 2006; 22: 111-7.
23. Hunt KJ, Resendez RG, Williams K, Haffner SM, Stern MP. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation. 2004; 110: 1251-7.
24. Hu FB, Stampfer MJ, Haffner SM, Solomon CG, Willett WC, Manson JE. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care. 2002; 25: 1129-34.
25. Bamba V, Rader DJ. Obesity and atherogenic dyslipidemia. Gastroenterology. 2007; 132: 2181-90.
26. Castelli WP. Epidemiology of triglycerides: A view from Framingham. Am J Cardiol. 1992; 70: H3-9.
27. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: A meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996; 3: 213-9.
28. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation. 2002; 106: 3143-421.
29. Elovson S, Chatterton CJ, Bell GT et al. Plasma very low density lipoproteins contain single molecule of apolipoprotein B. J Lipid Res. 1988; 29: 1461-73.
30. Pankow JS, Kwan DK, Duncan BB et al. Cardiometabolic risk in impired fasting glucose and impaired glucose tolerance. The Atherosclerosis Risk in Communities study. Diabetes Care. 2007; 30: 325-31.
31. Abdul-Ghani MA, Tripathy D, DeFronzo RA. Contributions of β-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care. 2006; 29: 1130-9.
32. Howard BV. Insulin resistance and lipid metabolism. Am J Cardiol. 1999; 84: J28-32.
33. DeFronzo RA, Ferrannini E. Insulin resistance: A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991; 14: 173-94.